Effect of dietary with Zhibai dihuang pills and gonadotropin-releasing-hormone-analogue on girls with precocious and rapidly progressive puberty

Table 1 Basic clinical data of children in the two groups (mean ± SD)

Group		Control group	Observation group	t/χ2	P value
Case (n)		42	42
Age	Maximum	10	11	0.079	0.694
	Minimum	6	6
	Average	8.79 ± 1.08	8.87 ± 1.17	0.354	0.443
Height (cm)	Maximum	141	144	3.977	0.051
	Minimum	113	111
	Average	126.59 ± 2.52	125.34 ± 2.40	1.679	0.098
Body quality (kg/m2)	Highest	20.69	21.38	0.760	0.308
	Lowest	15.35	15.30

Table 2 Comparison of clinical efficacy between the two groups

Group	Control group	Observation group	t/χ2	P value
Case (n)	42	42
Healing	0	5
Significant	17	25
Effective	15	9
Invalid	10	3
Total effective rate, n (%)	32 (76.19)	39 (92.86)	17.163	0.001

Table 3 Comparison of growth indicators between the two groups of children (mean ± SD)

Group	Control group	Observation group	t	P value
Growth rate (%)
Before intervention	4.56 ± 0.61	4.81 ± 0.75	1.715	0.090
After intervention	3.56 ± 0.59	2.25 ± 0.89	8.190	0.001
Height (cm)
Before intervention	125.26 ± 3.00	125.11 ± 2.95	0.222	0.829
After intervention	133.44 ± 2.33	127.81 ± 2.43	10.934	0.001
Bone age (year)
Before intervention	8.80 ± 0.50	8.91 ± 0.64	0.941	0.348
After intervention	9.24 ± 0.64	7.21 ± 0.33	18.836	0.001

Table 4 Comparison of ovarian function indicators between the two groups of children (mean ± SD)

Group	Control group	Observation group	t	P value
P (ng/mL)
Before intervention	4.76 ± 1.60	4.83 ± 1.69	0.141	0.891
After intervention	2.94 ± 0.73	2.14 ± 0.64	5.466	0.001
T (nmol/L)
Before intervention	6.78 ± 2.16	6.73 ± 2.22	0.148	0.881
After intervention	4.46 ± 1.44	3.11 ± 1.12	4.757	0.001
E2 (pg/mL)
Before intervention	30.34 ± 5.72	30.85 ± 5.69	0.387	0.706
After intervention	18.76 ± 2.92	11.44 ± 2.75	11.814	0.001
PRL (ng/mL)
Before intervention	12.76 ± 3.51	13.05 ± 3.64	0.370	0.712
After intervention	11.00 ± 2.54	8.93 ± 2.79	3.591	0.001
LH (U/L)
Before intervention	3.16 ± 0.08	3.19 ± 0.08	0.569	0.572
After intervention	2.14 ± 0.36	1.51 ± 0.27	9.314	0.001
FSH (IU/L)
Before intervention	15.22 ± 5.26	15.36 ± 5.15	0.123	0.913
After intervention	8.76 ± 2.57	6.27 ± 2.35	4.615	0.001

P: Progesterone; T: Testosterone; E2: Estradiol; PRL: Prolactin; LH: Luteinizing hormone; FSH: Follicle-stimulating hormone.

Table 5 Comparison of adverse reactions between the two groups of children, n (%)

Group	Control group	Observation group	Z	P value
Case	42	42
Sweat	1 (2.38)	0 (0)
Back pain	1 (2.38)	0 (0)
Dizziness	0	0
Dry mouth	1 (2.38)	1 (2.38)
Adverse reaction rate	3 (7.14)	1 (2.38)	0.216	0.641